This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Crizotinib (Xalcori) for locally advanced or metastatic Non‐Small Cell Lung Cancer (NSCLC)

< Back

Crizotinib (Xalcori) for locally advanced or metastatic Non‐Small Cell Lung Cancer (NSCLC)


Cancer and Palliative Care

April 2018

Non‐small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about ninety per cent of lung cancers in the UK. A small proportion of NSCLC tumours have a genetic change in a gene called c‐METexon14. When NSCLC tumours have advanced or spread to other organs there are very limited treatments available.
Crizotinib is an anticancer drug that can be taken up to twice a day orally as capsules. Crizotinib works by blocking the growth and spread of cancer cells that have c‐METexon14 changes to other parts of the body. Crizotinib is already approved for the treatment of a subtype of advanced NSCLC with a different genetic change (ALK mutations) in people that have been previously treated with chemotherapy. If approved for this new indication, crizotinib has the potential to prolong survival for patients with NSCLC and c‐MET gene alteration that have advanced or spread to other organs, for which no other treatment is available apart from best supportive care.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts